Dr. Xiaowei Nie is an Associate Professor in the Department of Human Cell Biology and Genetics in the School of Medicine, Southern University of Science and Technology's. She has been distinguished with the Shenzhen Outstanding Young Investigator Fund and is acknowledged as a high-level talent by both the Shenzhen City and Jiangsu Province governments. Dr. Nie has secured 10 government grants, including four from the prestigious National Natural Science Foundation of China. Her research has been recognized with accolades such as the Second Prize of the Chinese Medical Science and Technology Award and the First Prize of the Jiangsu Province Science and Technology Progress Award.

Dr. Nie is deeply involved in the study of the pathogenesis and therapeutic targets of pulmonary arterial hypertension. She has published 50 scientific papers in the field. As the lead or corresponding author, she has contributed 30 papers to esteemed journals, including Circulation, Immunity, and Circulation Research. Furthermore, Dr. Nie has been invited and elected as a full member of Sigma Xi, The Scientific Research Honor Society, based in the United States.

EDUCATION

Sep 2007 - Jun 2012  Harbin Medical University, M.D.

Sep 2000 - Jun 2004  Jiamusi University, B.Sc. in Pharmacy

EXPERIENCE

Jul 2024-Present: Associate Professor, Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China

Mar 2021-Jun 2024: Research Associate Professor, The First & Second Affiliated Hospital of Southern University of Science and Technology

May 2020-Feb 2021: Research Associate Professor, The Second Affiliated Hospital of Southern University of Science and Technology

Feb 2018-April 2020. Research Fellow, Department of Pharmacology, School of Medicine, National University of Singapore, Singapore

Nov 2014-Feb 2018. Deputy Director & Assistant Professor, Clinical Research Center, Wuxi People's Hospital Affiliated to Nanjing Medical University, of

Oct 2012-Oct 2014: Postdoctoral fellow, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Postdoctoral Researcher

RESEARCH INTERESTS

Pathogenesis, Diagnosis, and Therapeutic Targets of Pulmonary Arterial Hypertension.

We employ cutting-edge technology to analyze the expression levels of various extracellular matrix (ECM) proteins in the lung tissue and pulmonary arteries of patients with pulmonary arterial hypertension (PAH). Our research delves into the secretion and transport mechanisms of these ECM proteins to elucidate the pathogenesis behind vascular remodeling in PAH. Our overarching objective is to pinpoint reliable biological markers that can accurately predict clinical outcomes and to uncover novel therapeutic targets aimed at combating this challenging disease.

HONORS AND AWARDS

2024: First Prize for Science and Technology Progress in Jiangsu Province (Third Contributor)

2024: Full Member of Sigma Xi, The Scientific Research Honor Society, USA

2022: Shenzhen Outstanding Young Scientist Fund recipient 

2021: Shenzhen High Level Talent

2019: Third Prize of Chinese Medical Science and Technology Award (Third Contributor)

2019: Second Prize of Jiangsu Medical Science and Technology Award (Third Contributor)

2017: High-Level Talent in the 14th "Six Major Talent Plan" in Jiangsu Province

2016: Key Young Talent in Medicine under the "Science and Education Strengthening Health Project" in Jiangsu Province

BIBLIOGRAPHY

*Corresponding Author

1. Bian JS*#, Chen J#, Zhang J, Tan J, Chen Y, Yang X, Li Y, Deng L, Chen R, Nie X*. ErbB3 governs endothelial dysfunction in hypoxia-induced pulmonary hypertension. Circulation. 2024 Nov 5;150(19):1533-1553.

2. Zhang J; Li Y, Chen Y, Zhang J, Jia Z, He M, Liao X, He S, Bian JS*, Nie XW*. o8G site-specifically modified tRF-1-AspGTC: a novel therapeutic target and biomarker for pulmonary hypertension. Circulation Research, Circulation Research. 2024 Jun 21;135(1):76-92.

3. Huang S, Dong W, Lin X, Xu K, Li K, Xiong S, Wang Z, Nie X*, Bian JS*. Disruption of the Na+/K+-ATPase/P2X7R complex in the microglia contributes to stress-induced anxiety. Immunity, 2024, 57, 495–512.

4. Deng L， Cao C， Cai Z, Wang Z, Leng B, Chen Z, Kong F, Zhou Z, He J, Nie X*, Bian JS*. STING contributes to pulmonary hypertension by targeting the interferon and BMPR2 signaling through regulating F2RL3. American Journal of Respiratory Cell and Molecular Biology 2024;71(3):356-371.  

5. Zhang J#, Li Y#, Zhang J, Liu L, Chen Y, Yang X, Liao X, He M, Jia Z, Fan J, Bian JS*, Nie X*. ADAR1 regulates vascular remodeling in hypoxic pulmonary hypertension through N1-methyladenosine modification of circCDK17. Acta Pharm Sin B. 2023 Dec;13(12):4840-4855.

6. Sun HJ#, Tan J#, Xiong S#, Shan XD#, Wang ZC#, Wu ZY, Bian JS*, Nie X*. DR-region of NKAα1 is a target to ameliorate hepatic lipid metabolism disturbance in obese mice. METABOLISM-CLINICAL AND EXPERIMENTAL 2023:145:155579.

7. Deng L, Leng B, Nie X*. The cannabis paradox: contrasting role for marijuana in cardiovascular disease. Signal Transduct Target Ther 2022;7(1):309.

8. Cao L, Xiong S, Wu Z, Ding L, Zhou Y, Sun H, Zhu M, Lee WT, Nie X*, Bian JS*. Anti-Na+/K+-ATPase immunotherapy ameliorates α-synuclein pathology through activation of Na+/K+-ATPase α1-dependent autophagy. Science Advances 2021 Jan 27;7(5):eabc5062. doi: 10.1126/sciadv.abc5062.

9. Nie X*, Shen C, Tan J, Wu Z, Wang W, Chen Y, Dai Y, Yang X, Ye S, Chen J, Bian JS*. Periostin: A Potential Therapeutic Target For Pulmonary Hypertension? Circulation Research 2020;127(9):1138-1152.

10. Cao X, Cao L, Zhang W, Lu R, Bian JS*, Nie X*. Therapeutic potential of sulfur-containing natural products in inflammatory diseases. Pharmacol Ther 2020;216:107687.